Treatment with Epidiolex led to a range of improvements — from fewer seizures to improved cognition and better social skills — for both children and adults with Dravet syndrome and Lennox-Gastaut syndrome (LGS), according to new analyses of a U.S. caregiver survey. The results, presented in a pair…
News
Long-term treatment with soticlestat was found to reduce seizure frequency by more than 50% in most Dravet syndrome patients, according to about two years of data from the ongoing ENDYMION 1 clinical trial. “Soticlestat was associated with sustained seizure reductions over the interim period presented here,” researchers wrote.
Note: This article was updated April 21, 2023, to reflect that Fintepla was originally classified a Schedule IV controlled substance due to its low risk of abuse or misuse. A risk evaluation and mitigation strategy established by Zogenix that limits Fintepla’s access due to links with cardiovascular-related side effects remains…
Adopting a ketogenic diet — one low in carbohydrates and high in fat — safely and effectively reduces the frequency of seizures and improves cognitive function and behavior in children and adolescents with Dravet syndrome, according to a multicenter study in China. Nearly a third of patients were…
More severe epilepsy and greater behavioral challenges predict worse health-related quality of life (HRQoL) up to 10 years later in people with Dravet syndrome, a study has found. In addition, early use of sodium channel blockers — a type of anti-seizure medication that should be avoided in most…
Children and adults with Dravet syndrome commonly exhibit challenging behaviors such as aggression, dangerous behavior, and impulsivity, according to a Dutch study based on responses from 20 parents. These behaviors, apart from the seizures that are a hallmark of the disease, can greatly affect the quality of life of…
A higher single dose of STK-001 will be administered in the U.S.-based Phase 1/2a MONARCH trial that is testing Stoke Therapeutics’ experimental therapy in children and adolescents with Dravet syndrome. The U.S. Food and Drug Administration (FDA) allowed Stoke to test a 70 mg dose in the MONARCH…
To help ensure that those with Dravet syndrome receive high-quality care regardless of their financial situation, the Dravet Syndrome Foundation (DSF) again is offering its global Patient Assistance Grant (PAG) Program. “Medical expenses are high when you have a loved one with Dravet syndrome, and we know…
The Dravet Syndrome Foundation (DSF) is funding a collaborative research project to provide a framework for artificial intelligence (AI)-based analyses of data in the published scientific literature related to Dravet syndrome. The grant provides $240,000 over the next two years to support the project. The work will be…
A Phase 1 clinical trial that enrolled healthy volunteers to test BMB-101, Bright Minds Biosciences’ investigational treatment for Dravet syndrome, has moved to its final part, the company announced in a corporate update. This first-in-human trial of the oral therapy, which is testing BMB-101 at different doses,…
Recent Posts
- Cell study offers new clues to Dravet seizure triggers
- Epidiolex reduces seizures in rare Dravet syndrome cases: Study
- Faster-than-expected enrollment seen in trial testing zorevunersen for Dravet
- The little lost journal that brings back memories of our Dravet journey
- FDA grants breakthrough status to new gene therapy for Dravet syndrome
- First look at ETX101 suggests early benefits for children with Dravet
- Grief comes in waves and reminds me of the start of a long journey
- Stoke readies to meet with FDA on 4 years of zorevunersen study data
- Continuing family traditions helps keep my daughter’s memory alive
- FDA awards RMAT designation to Dravet syndrome gene therapy